Cancer Research Horizons (CRH) is harnessing the skills, expertise, and research network of its parent organization to speed-up the discovery and development of transformative oncology drugs, improve patient outcomes, and advance assets for biopharma partners.
Category: In the News
Episologen, Lonza manufacture first IgE to treat ovarian cancer
Epsilogen and Lonza have successfully completed large-scale GMP manufacturing of MOv18 IgE, to treat platinum-resistant ovarian cancer (PROC) patients.
2023 cancer research highlights: Drug development at its best
Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development.
As always, a year within cancer drug discovery and development brings with it significant breakthroughs, and 2023 has been no exception.
MOv18 – opening a new front for immunotherapy
Parasites, allergy and innovation – the journey to get the first IgE anti-cancer drug into a human was certainly not easy. Here we follow Sophia Karagiannis and James Spicer on an immunological adventure as they work with our Centre for Drug Discovery on this potentially ground-breaking new class of drug.
https://news.cancerresearchuk.org/2023/12/12/mov18-opening-a-new-front-for-immunotherapy/
The Life Sciences Future50
PwC’s UK Life Sciences Future50 celebrates a selection of companies that illustrate the world-class science and innovation by life sciences businesses in the UK, which are aiming to solve some of the most important challenges in scientific research and human healthcare.
Novartis backs Epsilogen’s bid to turn ‘Cinderella antibody’ into new class of cancer drug | Fierce Biotech
This article appeared in Fierce Biotech, March 2 2022
Epsilogen raises £30.8M series B to support testing IgE antibody against ovarian cancer | BioWorld
Epsilogen Ltd was profiled in BioWorld on March 2, 2022.
Epsilogen’s CEO speaks to Lu Rahman about their ongoing work in developing novel IgE antibodies to treat cancer.
This article first appeared in Drug Discovery World, Spring 2021, Volume 22, Issue 2.